High-dose Chemotherapy with Autologous Stem Cell Support in Advanced Ovarian Cancer

References

• Parkin D M, Pisani P, Ferlay J. Estimates of the world-wide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594–606
   PubMed Web of Science ®Google Scholar
• Piver M S, Baker T R, Piedmonte M, Sandecki A M. Epidemiology and etiology of ovarian cancer. Semin Oncol 1991; 18: 177–85
   PubMed Web of Science ®Google Scholar
• Annual Report on the Results of the Treatment in Gynecological Cancer. FIGO, F Pettersson, 1994
   Google Scholar
• Colombo N, Pittelli M, Parma G, et al. Cisplatin dose intensity in advanced ovarian cancer: a randomized study of conventional dose vs. dose-intense cisplatin mono-therapy. Proc Am Soc Clin Oncol 1993; 12: 255
   Google Scholar
• Podczaski E, Marietta A, Kaminski P, et al. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. Gynecol Oncol 1990; 36: 43–7
   PubMedGoogle Scholar
• Coldman A, Goldie J. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 1987; 14: 29–33
   PubMed Web of Science ®Google Scholar
• Kaye S B, Lewis C R, Paul J, et al. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329–33
   PubMed Web of Science ®Google Scholar
• Mc Guire W P, Hoskins W J, Brady M F, et al. Assesment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995a; 13: 1589–99
   PubMedGoogle Scholar
• Ozols R F, Thigpen J T, Dauplat J, et al. Dose intensity. Ann Oncol 1993; 4: S49–56, Suppl
   PubMedGoogle Scholar
• Thigpen T, Vance R, Puneky L, Khansur T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 1994a; 55: S97–107
   PubMed Web of Science ®Google Scholar
• de Vries E GE, Hamilton T C, Lind M, Dauplat J, Neijt J, Ozols R F. Drug resistance, supportive care and dose intensity. Ann Oncol 1993; 4: S57–62, Suppl
   PubMed Web of Science ®Google Scholar
• Menichella G, Pierelli L, Foddai M, et al. Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. Br J Haematol 1991; 79: 444–50
   PubMed Web of Science ®Google Scholar
• Murakami M, Shinozuka T, Kuroshima Y, Tokuda Y, Tajima T. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumours. Semin Oncol 1994; 21: 29–32, Suppl
   PubMed Web of Science ®Google Scholar
• Benedetti-Panici P, Greggi S, Scambia G, et al. High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Ann Med 1995; 27: 133–8
   PubMed Web of Science ®Google Scholar
• Fenelly D, Schneider Spriggs D, et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 1995; 13: 1160–6
   PubMedGoogle Scholar
• Woodhouse J R, Ferry D R. The genetic basis of resistance to cancer chemotherapy. Ann Med 1995; 27: 157–67
   PubMed Web of Science ®Google Scholar
• Lai G-M, Ozols R F, Smyth J F, Young R C, Hamilton T C. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 1988; 37: 4597–600
   PubMed Web of Science ®Google Scholar
• Parker R J, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772–7
   PubMed Web of Science ®Google Scholar
• Gottesman M M, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385–427
   PubMed Web of Science ®Google Scholar
• Kristensen G, Baekelandt M, Holm R, et al. PGP expression as a possible marker for response to cisplatin-epirubicin as a first-line treatment in advanced ovarian cancer. Gynecol Oncol 1995; 56: 110
   Google Scholar
• Holzmayer T, Hilsenbeck S, Von Hoff D D, et al. Clinical correlates of MDRI (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992; 84: 1486–91; 19
   PubMedGoogle Scholar
• O'Dwyer P J, Hamilton T C, Young R C, et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximin: clinical and biochemical results. J Natl Cancer Inst 1992; 84: 264–7
   PubMed Web of Science ®Google Scholar
• O'Dwyer P J, La Creta F, Nash J, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 1991; 51: 6059–65
   PubMed Web of Science ®Google Scholar
• Sessa C, Zucchetti M, Davoli E, et al. Phase I and clinical pharmacologic evaluation of aphidicolin glycinate. J Natl Cancer Inst 1991; 83: 1160–9
   PubMedGoogle Scholar
• Lowe S W, Ruley H E, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–67
   PubMed Web of Science ®Google Scholar
• Hockenbery Y D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–6
   PubMed Web of Science ®Google Scholar
• Alberts D S, Young L, Mason N L, et al. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985; 12: 38–42, Suppl
   PubMed Web of Science ®Google Scholar
• Skipper H E. Dose intensity vs. total dose of chemotherapy: an experimental basis. Important Advances in Oncology, V T De Vita, S Hellman, S A Rosenberg. JB Lippincott, New York 1990; 43–64
   Google Scholar
• Levin L, Hryniuk W M. Dose-intensity analysis of chemotherapeutic agents in ovarian cancer. J Clin Oncol 1987; 5: 756–67
   PubMed Web of Science ®Google Scholar
• Levin L, Simon R, Hryniuk W. Importance of multiagent chemotherapy regimens in ovarian cancer: dose intensity analysis. J Natl Cancer Inst 1993; 85: 1732–42
   PubMed Web of Science ®Google Scholar
• Ben-David Y, Rosen B, Franssen E, et al. Meta-analysis comparing cisplatin total dose intensity and survival. Gynecol Oncol 1995; 59: 93–101
   PubMedGoogle Scholar
• Caldas C, Morris L E, McGuire W P. Salvage therapy in epithelial ovarian cancer. Obstet Gynecol Clin North Am 1994; 21: 179–94
   PubMedGoogle Scholar
• Behrens B C, Hamilton T C, Masuda H, et al. Characteristics of cis-diamminedochloroplatinum (II)resistant human ovarian cell line and its evaluation of platinum analogues. Cancer Res 1987; 47: 414–8
   PubMed Web of Science ®Google Scholar
• Bertelssen K. Optimal chemotherapy of ovarian cancer with an old regimen. Ann Med 1995; 27: 121–5
   PubMedGoogle Scholar
• Mc Guire W P, Hoskins W J, Brady M F, et al. Taxol and cisplatin (TP) improves outcome in advanced ovarian cancer (AOC) as compare to cytoxan and cisplatin (CP). Proc Am Soc Clin Oncol 1995b; 14: 275
   Google Scholar
• Trimble E L, Arbuck S G, McGuire W P. Options for primary chemotherapy of epithelial ovarian cancer: Taxanes. Gynecol Oncol 1994; 55: S114–21
   PubMed Web of Science ®Google Scholar
• Christian M C, Trimble E L. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994; 55: S143–50
   Google Scholar
• Dauplat J, Legros M, Condat P, Ferrieri J P, Ben Ahmed S, Plagne R. High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation. Gynecol Oncol 1989; 34: 294–8
   PubMed Web of Science ®Google Scholar
• Viens P, Maraninchi D, Legros F, et al. High-dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 1990; 5: 227–33
   PubMed Web of Science ®Google Scholar
• Legros M, Fluery J, Cure H, et al. High dose chemotherapy (HDC) and autologous bone marrow transplant (ABMT) in 31 advanced ovarian cancers: long term results. Proc Am Soc Clin Oncol 1992; 11: 222
   Google Scholar
• Mulder P OM, Willemse P HB, Aalders J G, et al. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Cancer Clin Oncol 1989; 25: 645–9
   PubMedGoogle Scholar
• Shea T C, Flaherty M, Elias A, et al. A phase I clinical and pharmacokinetic study and carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651–61
   PubMed Web of Science ®Google Scholar
• Shpall E J, Clarke-Pearson D, Soper J T, et al. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 1990; 38: 386–91
   PubMed Web of Science ®Google Scholar
• Lotz J P, Machover D, Malassagne B, et al. Phase III study of two consecutive courses of high-dose epipodo-phyllotoxin, Ifosfamide, and Carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumours. J Clin Oncol 1991; 9: 1860–70
   PubMedGoogle Scholar
• Rebollo J H, Martin A S, Fernandez H O, et al. High dose combination of carboplatin (CBDCA) and etoposide (VP-16) followed by peripheral blood stem cell (PBSC) transplantation in the treatment of ovarian carcinoma. Proc Am Assos Cancer Res 1991; 32: 172
   Google Scholar
• Collins R H, Pineiro L, Fay J W. High-dose chemotherapy and autologous bone marrow transplantation for advanced ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: 233
   Google Scholar
• Extra J M, Dieras W, Giacchetti S, et al. High-dose chemotherapy (HCT) with autologous bone marrow reinfusion (ABMR) as consolidation therapy for patients (PTS) with advanced ovarian adeno carcinoma (AO). Proc Am Soc Clin Oncol 1992; 11: 234
   Google Scholar
• Shea T C, Storniolo A M, Mason J R, et al. High-dose intravenous (IV) and intraperitoneal (IP) combination chemotherapy with autologous stem cell rescue for patients with advanced ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: 236
   Google Scholar
• Lotz J P, Machover D, Bellaiche A, et al. Tandem high-dose (HD) chemotherapy (CT) with VM-26, ifosfamide (IFM), and carboplatin (CBDCA) with autologous bone marrow transplantation (ABMT) for patients with stage III C - IV ovarian cancer (OC). Proc Am Soc Clin Oncol 1993; 12: 257
   Google Scholar
• Broun E R, Belinson J L, Berek J S, et al. Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study. Gynecol Oncol 1994; 54: 142–6
   PubMed Web of Science ®Google Scholar
• Stiff P, Bayer R, Camarda M, et al. A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol 1995; 57: 278–85
   PubMed Web of Science ®Google Scholar
• Shpall E J, Cagnoni P J, Bearman S I, et al. High-dose chemotherapy with autologous hematopoetic cell support (AHCS) for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educational Book 1995a; 360–4
   Google Scholar
• Thigpen J T, Blessing J A, Ball H, Hummel S J, Barrett R J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994b; 12: 1748–53
   PubMed Web of Science ®Google Scholar
• Williams C J, Stewart L, Parmar M, et al. Meta-analysis of the role of platinum compounds in advanced ovarian cancer. Semin Oncol 1992; 19: 120–8
   PubMedGoogle Scholar
• Neijt J P, Bokkel Huinink W W, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367–72
   PubMedGoogle Scholar
• Muramatsu T, Shinozuka T, Hirasawa T, et al. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) in epithelial ovarian cancer. Int J Gynecol Cancer 1995; 5: 44, Suppl 1
   Google Scholar
• Shpall E J, Jones R B, Bearman S I, Purdy M R. Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support. Gynecol Oncol 1994; 54: 357–61
   PubMedGoogle Scholar
• Pujade-Lauraine E, Extra J M. Place of intensive therapy in ovarian cancer. Eurocancer. Paris 1995; 217–8; 95
   Google Scholar
• Alberts D, Liu P, Hannigan E, et al. Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs. IV CDDP/IV CPA in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG intergroup study (INT 0051). Proc Am Soc Clin Oncol 1995; 13: 273
   Google Scholar
• Kohn E C, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum resistant ovarian cancer. J Natl Cancer Inst 1994; 86: 18–24
   PubMed Web of Science ®Google Scholar
• Cagnoni P J, Stemmer S M, Matthes S, et al. Phase I trial of high dose paclitaxel (Taxol), cyclophosphamide and cicplatin with autolougs hematopoetic progenitor cell rescue. Proc Am Soc Clin Oncol 1995; 14: 477
   Web of Science ®Google Scholar
• Swenerton K, Eisenhauer E, ten Bokkel, Huinink W, et al. Taxol in relapsed ovarian cancer: high vs. low dose and short vs. long infusion. A European Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 1993; 12: 256
   Google Scholar
• National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994; 55: S4–14
   PubMed Web of Science ®Google Scholar
• Forsström J, Dalton K J. Artificial neural networks for decision support in clinical medicine. Ann Med 1995; 27: 509–7
   PubMed Web of Science ®Google Scholar